Spradlin, Jessica N.

Harnessing the anti-cancer natural product nimbolide for targeted protein degradation

Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 432

Deubiquitinase-targeting chimeras for targeted protein stabilization

Henning, N. J., Boike, L., Spradlin, J. N., Ward, C. C., Liu, G., Zhang, E., Belcher, B. P., Brittain, S. M., Hesse, M. J., Dovala, D., et al. (2022) · Nature Chemical Biology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 344

Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications

Henning, N. J., Manford, A. G., Spradlin, J. N., Brittain, S. M., Zhang, E., McKenna, J. M., Tallarico, J. A., Schirle, M., Rape, M., & Nomura, D. K. (2022) · Journal of the American Chemical Society

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 221

Chemoproteomics-enabled discovery of covalent RNF114-based degraders that mimic natural product function

Luo, M., Spradlin, J. N., Boike, L., Tong, B., Brittain, S. M., McKenna, J. M., Tallarico, J. A., Schirle, M., Maimone, T. J., & Nomura, D. K. (2021) · Cell Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 186

Reimagining Druggability Using Chemoproteomic Platforms

Spradlin, J. N., Zhang, E., & Nomura, D. K. (2021) · Accounts of Chemical Research

Click Chemistry and ApplicationsProtein Degradation and Inhibitors

Cited by 176

A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL

Tong, B., Spradlin, J. N., Novaes, L. F. T., Zhang, E., Hu, X., Moeller, M., Brittain, S. M., McGregor, L. M., McKenna, J. M., Tallarico, J. A., et al. (2020) · ACS Chemical Biology

Protein Degradation and InhibitorsChemical Synthesis and Analysis

Cited by 118

Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2

Biering, S. B., Van Dis, E., Wehri, E., Yamashiro, L. H., Wrynla, X. H., Dugast-Darzacq, C., Graham, T. G. W., Stroumza, J. R., Golovkine, G. R., Roberts, A. W., et al. (2021) · ACS Infectious Diseases

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 28